Analyst Optimistic on Terns (TERN) Citing Doable $4.8B Marketplace for Upcoming Leukemia Drug
Terns Prescribed drugs Inc. (NASDAQ:TERN) is one in every of 15 shares with the most important hedge fund momentum, after gaining 42 hedge fund holders through the fourth quarter of 2025. On February 9, Leerink Companions initiated protection on Terns Prescribed drugs Inc. (NASDAQ:TERN) with an Outperform score and a value goal of $58.
Leerink Companions famous that TERN-701, Terns Prescribed drugs Inc. (NASDAQ:TERN)’s next-generation allosteric inhibitor being developed for power myeloid leukemia, addresses a market with established focused remedy adoption. The agency expects a $4.8 billion alternative for TERN-701, whereas forecasting a further $1.4 billion in second-line and past peak revenues.
The analyst agency additionally mentioned that TERN-701 builds upon the medical and industrial success of allosteric inhibition established by Novartis’s Scemblix, which is at the moment on a $1.6 billion run charge as of the fourth quarter of 2025. Early Part 1 knowledge from the CARDINAL trial counsel TERN-701 might have a best-in-class profile, with larger molecular response charges and a clear security profile that permits deeper and extra sturdy goal suppression, in line with the analysis agency.
Terns Prescribed drugs Inc. (NASDAQ:TERN) is a clinical-stage biopharmaceutical firm that develops a portfolio of small-molecule single-agent and mixture remedy candidates for the therapy of non-alcoholic steatohepatitis and different power liver ailments.
Whereas we acknowledge the potential of TERN as an funding, we consider sure AI shares provide higher upside potential and carry much less draw back danger. If you happen to’re on the lookout for a particularly undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring development, see our free report on the greatest short-term AI inventory.
READ NEXT: 13 Sizzling Shares to Purchase with the Highest Upside Potential and 10 Greatest Excessive-Upside Supplies Shares to Purchase
Disclosure: None. Observe Insider Monkey on Google Information.
